Summary of Baxter International FY Conference Call (March 11, 2026) Company Overview - **Company**: Baxter International (NYSE:BAX) - **Date of Conference**: March 11, 2026 - **Key Speakers**: Joel Grade (EVP, CFO), Kevin Moran (Investor Relations) Key Points Industry and Market Context - **Geopolitical Impact**: Baxter has minimal exposure to the Middle East, with revenue described as "sub 2" million, indicating limited business operations in that region [11][13][15] - **Energy Costs**: The company's exposure to oil price fluctuations has decreased to less than half compared to previous assessments made during the 2022 investor day. Previously, a $10 increase in oil prices would impact Baxter by $25 million; this impact is now less than half of that [18][20][36] Financial Performance and Guidance - **Operational Changes**: The company has undergone significant restructuring, including the sale of BPS and verticalization of its business structure, which is expected to enhance operational efficiency and predictability [52][54] - **New Operating Model**: The introduction of the Growth and Performance Systems (GPS) aims to improve goal setting, KPI tracking, and overall operational cadence, leading to better forecasting and margin expansion over time [54][55] - **Product Performance**: The Advanced Surgery and Hospital Solutions Technologies (HST) segments have shown strong performance, with a solid order book and good global demand for differentiated products [63][64] Business Segments - **Advanced Surgery**: Continues to produce well-received products with strong global demand, expected to remain a margin-accretive business [63] - **HST**: Experienced a good year, with a focus on innovation and new product launches, including the Connex 360 monitoring device and the Dynamo stretcher [90][94] - **Pharmaceuticals**: Drug compounding is a strong growth area, although challenges remain in the injectables and anesthesia space due to operational issues and market conditions [71][72] Challenges and Risks - **Product Sales**: Baxter does not expect to sell Novum pumps through 2026 due to regulatory uncertainties, although sales of Spectrum pumps remain strong [82][88] - **Margin Pressures**: Higher inventory costs and tariff impacts are expected to affect margins in the first half of 2026, but improvements are anticipated in the second half due to restructuring and new product launches [97][98][100] Strategic Focus - **Innovation and Customer-Centric Approach**: The company emphasizes innovation and customer-centric product development as key drivers for future growth [94][95] - **Operational Efficiency**: Efforts to streamline management layers and reduce infrastructure costs are aimed at creating a more agile organization [55][60] Conclusion - Baxter International is navigating a complex market environment with strategic changes aimed at enhancing operational efficiency and product innovation. The company is positioned for growth in key segments, although it faces challenges related to regulatory issues and margin pressures. The focus on GPS and restructuring is expected to yield positive results in the long term.

Summary of Baxter International 2026 Conference Call Company Overview - **Company**: Baxter International (NYSE: BAX) - **Date of Conference**: February 26, 2026 Key Industry Insights - **Medtech Fundamentals**: The underlying fundamentals of the medtech industry are described as solid and stable, despite stock performance concerns. Patient volumes and procedure volumes are in a decent place, with no significant hyperinflationary pressures noted [12][13]. - **IV Solutions Market**: Demand for IV solutions has decreased by approximately 10-15% from pre-hurricane levels, establishing a new baseline for the market. This decline is attributed to changes in clinical practices following a hurricane [13][14][41]. Company-Specific Developments - **Leadership Changes**: The arrival of a new CEO, Andrew, is seen as timely for Baxter, allowing the company to build on a clearer operational foundation after recent distractions from divestitures [20][21]. - **Operational Model**: The introduction of a new operating model (GPS) aims to enhance consistency in operations and performance tracking. This model is expected to lead to improved operational predictability [22]. - **Verticalization Strategy**: Baxter is evolving its business structure to allow for end-to-end ownership of profit and loss (P&L), moving away from a country-led structure. This change is intended to streamline decision-making and improve accountability [29][30][37]. Financial Performance and Guidance - **2026 Guidance**: The guidance for 2026 is described as prudent, factoring in challenges and opportunities. It does not include any sales from the Novum product, which is under a voluntary shipping hold [101][103]. - **Margin Expectations**: The company anticipates sequential improvement in gross and operating margins throughout 2026, particularly in the second half of the year, as operational issues are resolved [116][118]. - **Capital Allocation**: Baxter is focused on deleveraging its balance sheet, targeting a debt-to-EBITDA ratio of three times by the end of the year. Internal investments in R&D and capital spending remain a priority [131][134]. Product Innovations - **New Products**: The Connex 360, a next-generation monitoring device, and the Dynamo, a connected stretcher, are highlighted as key innovations expected to drive growth in 2026. Customer feedback has been positive for these products [76][78]. Challenges and Risks - **Supply Chain Issues**: The company has faced supply challenges in its pharmaceutical business, which have impacted production and market performance. These issues are expected to improve in the second half of 2026 [47][110]. - **Tariff Changes**: Uncertainty surrounding tariff changes is acknowledged, with ongoing efforts to assess their impact on the business [99][100]. Conclusion - Baxter International is positioned at a pivotal point, focusing on stabilizing operations, improving financial performance, and driving innovation. The company aims to build credibility with stakeholders through consistent execution and strategic growth initiatives as it moves into 2026 [145][151].